A federal court has thrown out a lawsuit brought by ViroPharma (VPHM +0.2%) against the FDA that sought to stop the agency from approving three generic versions of the company's antibiotic Vancocin, saying the drug developer failed to produce any new evidence. Vancocin, a treatment for Clostridium difficile and other gastrointestinal infections, accounted for about $289M in VPHM’s sales in 2011, and constitutes about half of its revenue.
A federal court has thrown out a lawsuit brought by ViroPharma (VPHM +0.2%) against the FDA that...
From other sites
at CNBC.com (Jun 8, 2015)
at CNBC.com (May 21, 2015)
at CNBC.com (Jan 16, 2015)
at CNBC.com (Jan 15, 2015)
at CNBC.com (Jan 13, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs